 Global GABA Receptor Agonists Market Growth 2026-2032
The global GABA Receptor Agonists market size is predicted to grow from US$ 4549 million in 2025 to US$ 7654 million in 2032; it is expected to grow at a CAGR of 7.7% from 2026 to 2032. GABA recep... もっと見る
SummaryThe global GABA Receptor Agonists market size is predicted to grow from US$ 4549 million in 2025 to US$ 7654 million in 2032; it is expected to grow at a CAGR of 7.7% from 2026 to 2032.GABA receptor agonists are prescription drugs and clinical formulations that target gamma-aminobutyric acid receptors in the central nervous system and either directly activate the receptors or, under a broader commercial market scope, enhance receptor-mediated inhibitory neurotransmission. They are not a single physical product form, but pharmaceutical products composed of active pharmaceutical ingredients, excipients, packaging materials, and delivery systems. Typical forms include white to off-white crystalline active ingredients, tablets, capsules, granules, oral suspensions, orally disintegrating tablets, injections, and lyophilized powders for injection. By receptor and pharmacological mechanism, they can be divided into GABA_A receptor-targeted drugs, GABA_B receptor-targeted drugs, partial agonists, positive allosteric modulators, and other GABAergic receptor-related drugs. Key technical requirements include stereochemical or polymorph control, impurity profiling, residual solvent control, immediate-release or sustained-release formulation design, aseptic filling, controlled-substance compliance, stability validation, and clinical therapeutic-window assessment. Their mechanism is to enhance inhibitory neurotransmission mediated by chloride channels or G-protein-coupled signaling, reduce neuronal excitability, and support treatment in spasticity, epilepsy, insomnia, procedural sedation and anesthesia, and selected rare neurological disorders. Market development opportunities are mainly driven by long-term therapeutic demand in neurological and psychiatric disorders. Population aging, high prevalence of sleep disorders, a stable patient base in epilepsy and spasticity, increasing procedural sedation needs, and the approval of therapies for rare neurodevelopmental disorders are moving this category beyond mature low-priced generics toward specialty, pediatric, orphan-drug, and differentiated formulation markets. The strongest opportunities are expected in receptor subtype selectivity, partial agonism, short-acting and controllable pharmacology, lower residual sedation, reduced dependence potential, and dosage forms better suited for special populations. The main market challenges are safety, abuse liability, and regulatory control. Traditional sedative-hypnotic and anxiolytic drugs are associated with somnolence, cognitive impairment, fall risk, respiratory depression, tolerance, physical dependence, and withdrawal or rebound effects. Several products are controlled substances, which raises compliance requirements for prescribing, manufacturing, distribution, and pharmacovigilance. Mature molecules face intense generic competition and persistent price erosion, while innovative drugs must prove clinical endpoints, long-term safety, reimbursement value, and differentiation against orexin receptor antagonists and newer non-GABA mechanisms in epilepsy and sleep medicine. Downstream demand is shifting from broad sedation and empirical use toward more precise indication-based management. Hospitals increasingly value controllability, rapid onset and offset, and convenient administration in anesthesia, intensive care, epilepsy, and spasticity treatment. Retail and outpatient channels are focusing on standardized short-course use for insomnia and anxiety-related symptoms. Specialty demand is expanding into pediatric rare epilepsy, neurodevelopmental disorders, elderly patients, and patients with multiple comorbidities. Future growth is therefore unlikely to come from unrestricted prescription expansion; it will mainly come from safer products, clearer indications, better formulations, and substitution of older agents with improved therapeutic profiles. LP Information, Inc. (LPI) ' newest research report, the “GABA Receptor Agonists Industry Forecast” looks at past sales and reviews total world GABA Receptor Agonists sales in 2025, providing a comprehensive analysis by region and market sector of projected GABA Receptor Agonists sales for 2026 through 2032. With GABA Receptor Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GABA Receptor Agonists industry. This Insight Report provides a comprehensive analysis of the global GABA Receptor Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GABA Receptor Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GABA Receptor Agonists market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GABA Receptor Agonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GABA Receptor Agonists. This report presents a comprehensive overview, market shares, and growth opportunities of GABA Receptor Agonists market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: GABA_A receptor-targeted drugs GABA_B receptor-targeted drugs Others Segmentation by Pharmacological Action Mode: Direct GABA receptor agonists Positive allosteric modulators Others Segmentation by Dosage Form: Oral dosage forms Injectable dosage forms Others Segmentation by Application: Attention Deficit Hyperactivity Disorder (ADHD) Psychiatric Disorders and Depression Alzheimer Epilepsy and Seizure Anxiety and Sleep Disorders Obesity and Alcoholism This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration. Sanofi Roche Novartis Viatris Teva Pharmaceutical Industries Sandoz Lundbeck Biocodex Immedica Pharma Azurity Pharmaceuticals Amneal Pharmaceuticals Fresenius Kabi Hikma Pharmaceuticals Eagle Pharmaceuticals PAION Pharma Mundipharma Eisai Sumitomo Pharma ANI Pharmaceuticals Zydus Lifesciences Aurobindo Pharma Sun Pharmaceutical Industries Cipla Torrent Pharmaceuticals Endo Baxter Hameln Pharma Ethypharm Neuraxpharm Sawai Pharmaceutical Towa Pharmaceutical Nichi-Iko Pharmaceutical Zhejiang Jingxin Pharmaceutical Jiangsu Nhwa Pharmaceutical Yichang Humanwell Pharmaceutical Shandong Sine Pharmaceutical Shanghai SPH Sine Pharmaceutical Key Questions Addressed in this Report What is the 10-year outlook for the global GABA Receptor Agonists market? What factors are driving GABA Receptor Agonists market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do GABA Receptor Agonists market opportunities vary by end market size? How does GABA Receptor Agonists break out by Type, by Application? Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global GABA Receptor Agonists Annual Sales 2021-2032 2.1.2 World Current & Future Analysis for GABA Receptor Agonists by Geographic Region, 2021, 2025 & 2032 2.1.3 World Current & Future Analysis for GABA Receptor Agonists by Country/Region, 2021, 2025 & 2032 2.2 GABA Receptor Agonists Segment by Type 2.2.1 GABA_A receptor-targeted drugs 2.2.2 GABA_B receptor-targeted drugs 2.2.3 Others 2.2.4 GABA Receptor Agonists Sales by Type 2.2.4.1 Global GABA Receptor Agonists Sales Market Share by Type (2021-2026) 2.2.4.2 Global GABA Receptor Agonists Revenue and Market Share by Type (2021-2026) 2.2.4.3 Global GABA Receptor Agonists Sale Price by Type (2021-2026) 2.3 GABA Receptor Agonists Segment by Pharmacological Action Mode 2.3.1 Direct GABA receptor agonists 2.3.2 Positive allosteric modulators 2.3.3 Others 2.3.4 GABA Receptor Agonists Sales by Pharmacological Action Mode 2.3.4.1 Global GABA Receptor Agonists Sales Market Share by Pharmacological Action Mode (2021-2026) 2.3.4.2 Global GABA Receptor Agonists Revenue and Market Share by Pharmacological Action Mode (2021-2026) 2.3.4.3 Global GABA Receptor Agonists Sale Price by Pharmacological Action Mode (2021-2026) 2.4 GABA Receptor Agonists Segment by Dosage Form 2.4.1 Oral dosage forms 2.4.2 Injectable dosage forms 2.4.3 Others 2.4.4 GABA Receptor Agonists Sales by Dosage Form 2.4.4.1 Global GABA Receptor Agonists Sales Market Share by Dosage Form (2021-2026) 2.4.4.2 Global GABA Receptor Agonists Revenue and Market Share by Dosage Form (2021-2026) 2.4.4.3 Global GABA Receptor Agonists Sale Price by Dosage Form (2021-2026) 2.5 GABA Receptor Agonists Segment by Application 2.5.1 Attention Deficit Hyperactivity Disorder (ADHD) 2.5.2 Psychiatric Disorders and Depression 2.5.3 Alzheimer 2.5.4 Epilepsy and Seizure 2.5.5 Anxiety and Sleep Disorders 2.5.6 Obesity and Alcoholism 2.5.7 GABA Receptor Agonists Sales by Application 2.5.7.1 Global GABA Receptor Agonists Sale Market Share by Application (2021-2026) 2.5.7.2 Global GABA Receptor Agonists Revenue and Market Share by Application (2021-2026) 2.5.7.3 Global GABA Receptor Agonists Sale Price by Application (2021-2026) 3 Global by Company 3.1 Global GABA Receptor Agonists Breakdown Data by Company 3.1.1 Global GABA Receptor Agonists Annual Sales by Company (2021-2026) 3.1.2 Global GABA Receptor Agonists Sales Market Share by Company (2021-2026) 3.2 Global GABA Receptor Agonists Annual Revenue by Company (2021-2026) 3.2.1 Global GABA Receptor Agonists Revenue by Company (2021-2026) 3.2.2 Global GABA Receptor Agonists Revenue Market Share by Company (2021-2026) 3.3 Global GABA Receptor Agonists Sale Price by Company 3.4 Key Manufacturers GABA Receptor Agonists Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers GABA Receptor Agonists Product Location Distribution 3.4.2 Players GABA Receptor Agonists Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for GABA Receptor Agonists by Geographic Region 4.1 World Historic GABA Receptor Agonists Market Size by Geographic Region (2021-2026) 4.1.1 Global GABA Receptor Agonists Annual Sales by Geographic Region (2021-2026) 4.1.2 Global GABA Receptor Agonists Annual Revenue by Geographic Region (2021-2026) 4.2 World Historic GABA Receptor Agonists Market Size by Country/Region (2021-2026) 4.2.1 Global GABA Receptor Agonists Annual Sales by Country/Region (2021-2026) 4.2.2 Global GABA Receptor Agonists Annual Revenue by Country/Region (2021-2026) 4.3 Americas GABA Receptor Agonists Sales Growth 4.4 APAC GABA Receptor Agonists Sales Growth 4.5 Europe GABA Receptor Agonists Sales Growth 4.6 Middle East & Africa GABA Receptor Agonists Sales Growth 5 Americas 5.1 Americas GABA Receptor Agonists Sales by Country 5.1.1 Americas GABA Receptor Agonists Sales by Country (2021-2026) 5.1.2 Americas GABA Receptor Agonists Revenue by Country (2021-2026) 5.2 Americas GABA Receptor Agonists Sales by Type (2021-2026) 5.3 Americas GABA Receptor Agonists Sales by Application (2021-2026) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC GABA Receptor Agonists Sales by Region 6.1.1 APAC GABA Receptor Agonists Sales by Region (2021-2026) 6.1.2 APAC GABA Receptor Agonists Revenue by Region (2021-2026) 6.2 APAC GABA Receptor Agonists Sales by Type (2021-2026) 6.3 APAC GABA Receptor Agonists Sales by Application (2021-2026) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe GABA Receptor Agonists by Country 7.1.1 Europe GABA Receptor Agonists Sales by Country (2021-2026) 7.1.2 Europe GABA Receptor Agonists Revenue by Country (2021-2026) 7.2 Europe GABA Receptor Agonists Sales by Type (2021-2026) 7.3 Europe GABA Receptor Agonists Sales by Application (2021-2026) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa GABA Receptor Agonists by Country 8.1.1 Middle East & Africa GABA Receptor Agonists Sales by Country (2021-2026) 8.1.2 Middle East & Africa GABA Receptor Agonists Revenue by Country (2021-2026) 8.2 Middle East & Africa GABA Receptor Agonists Sales by Type (2021-2026) 8.3 Middle East & Africa GABA Receptor Agonists Sales by Application (2021-2026) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of GABA Receptor Agonists 10.3 Manufacturing Process Analysis of GABA Receptor Agonists 10.4 Industry Chain Structure of GABA Receptor Agonists 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 GABA Receptor Agonists Distributors 11.3 GABA Receptor Agonists Customer 12 World Forecast Review for GABA Receptor Agonists by Geographic Region 12.1 Global GABA Receptor Agonists Market Size Forecast by Region 12.1.1 Global GABA Receptor Agonists Forecast by Region (2027-2032) 12.1.2 Global GABA Receptor Agonists Annual Revenue Forecast by Region (2027-2032) 12.2 Americas Forecast by Country (2027-2032) 12.3 APAC Forecast by Region (2027-2032) 12.4 Europe Forecast by Country (2027-2032) 12.5 Middle East & Africa Forecast by Country (2027-2032) 12.6 Global GABA Receptor Agonists Forecast by Type (2027-2032) 12.7 Global GABA Receptor Agonists Forecast by Application (2027-2032) 13 Key Players Analysis 13.1 Sanofi 13.1.1 Sanofi Company Information 13.1.2 Sanofi GABA Receptor Agonists Product Portfolios and Specifications 13.1.3 Sanofi GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.1.4 Sanofi Main Business Overview 13.1.5 Sanofi Latest Developments 13.2 Roche 13.2.1 Roche Company Information 13.2.2 Roche GABA Receptor Agonists Product Portfolios and Specifications 13.2.3 Roche GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.2.4 Roche Main Business Overview 13.2.5 Roche Latest Developments 13.3 Novartis 13.3.1 Novartis Company Information 13.3.2 Novartis GABA Receptor Agonists Product Portfolios and Specifications 13.3.3 Novartis GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.3.4 Novartis Main Business Overview 13.3.5 Novartis Latest Developments 13.4 Viatris 13.4.1 Viatris Company Information 13.4.2 Viatris GABA Receptor Agonists Product Portfolios and Specifications 13.4.3 Viatris GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.4.4 Viatris Main Business Overview 13.4.5 Viatris Latest Developments 13.5 Teva Pharmaceutical Industries 13.5.1 Teva Pharmaceutical Industries Company Information 13.5.2 Teva Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications 13.5.3 Teva Pharmaceutical Industries GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.5.4 Teva Pharmaceutical Industries Main Business Overview 13.5.5 Teva Pharmaceutical Industries Latest Developments 13.6 Sandoz 13.6.1 Sandoz Company Information 13.6.2 Sandoz GABA Receptor Agonists Product Portfolios and Specifications 13.6.3 Sandoz GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.6.4 Sandoz Main Business Overview 13.6.5 Sandoz Latest Developments 13.7 Lundbeck 13.7.1 Lundbeck Company Information 13.7.2 Lundbeck GABA Receptor Agonists Product Portfolios and Specifications 13.7.3 Lundbeck GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.7.4 Lundbeck Main Business Overview 13.7.5 Lundbeck Latest Developments 13.8 Biocodex 13.8.1 Biocodex Company Information 13.8.2 Biocodex GABA Receptor Agonists Product Portfolios and Specifications 13.8.3 Biocodex GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.8.4 Biocodex Main Business Overview 13.8.5 Biocodex Latest Developments 13.9 Immedica Pharma 13.9.1 Immedica Pharma Company Information 13.9.2 Immedica Pharma GABA Receptor Agonists Product Portfolios and Specifications 13.9.3 Immedica Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.9.4 Immedica Pharma Main Business Overview 13.9.5 Immedica Pharma Latest Developments 13.10 Azurity Pharmaceuticals 13.10.1 Azurity Pharmaceuticals Company Information 13.10.2 Azurity Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications 13.10.3 Azurity Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.10.4 Azurity Pharmaceuticals Main Business Overview 13.10.5 Azurity Pharmaceuticals Latest Developments 13.11 Amneal Pharmaceuticals 13.11.1 Amneal Pharmaceuticals Company Information 13.11.2 Amneal Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications 13.11.3 Amneal Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.11.4 Amneal Pharmaceuticals Main Business Overview 13.11.5 Amneal Pharmaceuticals Latest Developments 13.12 Fresenius Kabi 13.12.1 Fresenius Kabi Company Information 13.12.2 Fresenius Kabi GABA Receptor Agonists Product Portfolios and Specifications 13.12.3 Fresenius Kabi GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.12.4 Fresenius Kabi Main Business Overview 13.12.5 Fresenius Kabi Latest Developments 13.13 Hikma Pharmaceuticals 13.13.1 Hikma Pharmaceuticals Company Information 13.13.2 Hikma Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications 13.13.3 Hikma Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.13.4 Hikma Pharmaceuticals Main Business Overview 13.13.5 Hikma Pharmaceuticals Latest Developments 13.14 Eagle Pharmaceuticals 13.14.1 Eagle Pharmaceuticals Company Information 13.14.2 Eagle Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications 13.14.3 Eagle Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.14.4 Eagle Pharmaceuticals Main Business Overview 13.14.5 Eagle Pharmaceuticals Latest Developments 13.15 PAION Pharma 13.15.1 PAION Pharma Company Information 13.15.2 PAION Pharma GABA Receptor Agonists Product Portfolios and Specifications 13.15.3 PAION Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.15.4 PAION Pharma Main Business Overview 13.15.5 PAION Pharma Latest Developments 13.16 Mundipharma 13.16.1 Mundipharma Company Information 13.16.2 Mundipharma GABA Receptor Agonists Product Portfolios and Specifications 13.16.3 Mundipharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.16.4 Mundipharma Main Business Overview 13.16.5 Mundipharma Latest Developments 13.17 Eisai 13.17.1 Eisai Company Information 13.17.2 Eisai GABA Receptor Agonists Product Portfolios and Specifications 13.17.3 Eisai GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.17.4 Eisai Main Business Overview 13.17.5 Eisai Latest Developments 13.18 Sumitomo Pharma 13.18.1 Sumitomo Pharma Company Information 13.18.2 Sumitomo Pharma GABA Receptor Agonists Product Portfolios and Specifications 13.18.3 Sumitomo Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.18.4 Sumitomo Pharma Main Business Overview 13.18.5 Sumitomo Pharma Latest Developments 13.19 ANI Pharmaceuticals 13.19.1 ANI Pharmaceuticals Company Information 13.19.2 ANI Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications 13.19.3 ANI Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.19.4 ANI Pharmaceuticals Main Business Overview 13.19.5 ANI Pharmaceuticals Latest Developments 13.20 Zydus Lifesciences 13.20.1 Zydus Lifesciences Company Information 13.20.2 Zydus Lifesciences GABA Receptor Agonists Product Portfolios and Specifications 13.20.3 Zydus Lifesciences GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.20.4 Zydus Lifesciences Main Business Overview 13.20.5 Zydus Lifesciences Latest Developments 13.21 Aurobindo Pharma 13.21.1 Aurobindo Pharma Company Information 13.21.2 Aurobindo Pharma GABA Receptor Agonists Product Portfolios and Specifications 13.21.3 Aurobindo Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.21.4 Aurobindo Pharma Main Business Overview 13.21.5 Aurobindo Pharma Latest Developments 13.22 Sun Pharmaceutical Industries 13.22.1 Sun Pharmaceutical Industries Company Information 13.22.2 Sun Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications 13.22.3 Sun Pharmaceutical Industries GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.22.4 Sun Pharmaceutical Industries Main Business Overview 13.22.5 Sun Pharmaceutical Industries Latest Developments 13.23 Cipla 13.23.1 Cipla Company Information 13.23.2 Cipla GABA Receptor Agonists Product Portfolios and Specifications 13.23.3 Cipla GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.23.4 Cipla Main Business Overview 13.23.5 Cipla Latest Developments 13.24 Torrent Pharmaceuticals 13.24.1 Torrent Pharmaceuticals Company Information 13.24.2 Torrent Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications 13.24.3 Torrent Pharmaceuticals GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.24.4 Torrent Pharmaceuticals Main Business Overview 13.24.5 Torrent Pharmaceuticals Latest Developments 13.25 Endo 13.25.1 Endo Company Information 13.25.2 Endo GABA Receptor Agonists Product Portfolios and Specifications 13.25.3 Endo GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.25.4 Endo Main Business Overview 13.25.5 Endo Latest Developments 13.26 Baxter 13.26.1 Baxter Company Information 13.26.2 Baxter GABA Receptor Agonists Product Portfolios and Specifications 13.26.3 Baxter GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.26.4 Baxter Main Business Overview 13.26.5 Baxter Latest Developments 13.27 Hameln Pharma 13.27.1 Hameln Pharma Company Information 13.27.2 Hameln Pharma GABA Receptor Agonists Product Portfolios and Specifications 13.27.3 Hameln Pharma GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.27.4 Hameln Pharma Main Business Overview 13.27.5 Hameln Pharma Latest Developments 13.28 Ethypharm 13.28.1 Ethypharm Company Information 13.28.2 Ethypharm GABA Receptor Agonists Product Portfolios and Specifications 13.28.3 Ethypharm GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.28.4 Ethypharm Main Business Overview 13.28.5 Ethypharm Latest Developments 13.29 Neuraxpharm 13.29.1 Neuraxpharm Company Information 13.29.2 Neuraxpharm GABA Receptor Agonists Product Portfolios and Specifications 13.29.3 Neuraxpharm GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.29.4 Neuraxpharm Main Business Overview 13.29.5 Neuraxpharm Latest Developments 13.30 Sawai Pharmaceutical 13.30.1 Sawai Pharmaceutical Company Information 13.30.2 Sawai Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.30.3 Sawai Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.30.4 Sawai Pharmaceutical Main Business Overview 13.30.5 Sawai Pharmaceutical Latest Developments 13.31 Towa Pharmaceutical 13.31.1 Towa Pharmaceutical Company Information 13.31.2 Towa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.31.3 Towa Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.31.4 Towa Pharmaceutical Main Business Overview 13.31.5 Towa Pharmaceutical Latest Developments 13.32 Nichi-Iko Pharmaceutical 13.32.1 Nichi-Iko Pharmaceutical Company Information 13.32.2 Nichi-Iko Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.32.3 Nichi-Iko Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.32.4 Nichi-Iko Pharmaceutical Main Business Overview 13.32.5 Nichi-Iko Pharmaceutical Latest Developments 13.33 Zhejiang Jingxin Pharmaceutical 13.33.1 Zhejiang Jingxin Pharmaceutical Company Information 13.33.2 Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.33.3 Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.33.4 Zhejiang Jingxin Pharmaceutical Main Business Overview 13.33.5 Zhejiang Jingxin Pharmaceutical Latest Developments 13.34 Jiangsu Nhwa Pharmaceutical 13.34.1 Jiangsu Nhwa Pharmaceutical Company Information 13.34.2 Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.34.3 Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.34.4 Jiangsu Nhwa Pharmaceutical Main Business Overview 13.34.5 Jiangsu Nhwa Pharmaceutical Latest Developments 13.35 Yichang Humanwell Pharmaceutical 13.35.1 Yichang Humanwell Pharmaceutical Company Information 13.35.2 Yichang Humanwell Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.35.3 Yichang Humanwell Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.35.4 Yichang Humanwell Pharmaceutical Main Business Overview 13.35.5 Yichang Humanwell Pharmaceutical Latest Developments 13.36 Shandong Sine Pharmaceutical 13.36.1 Shandong Sine Pharmaceutical Company Information 13.36.2 Shandong Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.36.3 Shandong Sine Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.36.4 Shandong Sine Pharmaceutical Main Business Overview 13.36.5 Shandong Sine Pharmaceutical Latest Developments 13.37 Shanghai SPH Sine Pharmaceutical 13.37.1 Shanghai SPH Sine Pharmaceutical Company Information 13.37.2 Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications 13.37.3 Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Sales, Revenue, Price and Gross Margin (2021-2026) 13.37.4 Shanghai SPH Sine Pharmaceutical Main Business Overview 13.37.5 Shanghai SPH Sine Pharmaceutical Latest Developments 14 Research Findings and Conclusion List of Tables/GraphsList of TablesTable 1. GABA Receptor Agonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions) Table 2. GABA Receptor Agonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions) Table 3. Major Players of GABA_A receptor-targeted drugs Table 4. Major Players of GABA_B receptor-targeted drugs Table 5. Major Players of Others Table 6. Global GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose) Table 7. Global GABA Receptor Agonists Sales Market Share by Type (2021-2026) Table 8. Global GABA Receptor Agonists Revenue by Type (2021-2026) & ($ million) Table 9. Global GABA Receptor Agonists Revenue Market Share by Type (2021-2026) Table 10. Global GABA Receptor Agonists Sale Price by Type (2021-2026) & (USD/Pcs) Table 11. Major Players of Direct GABA receptor agonists Table 12. Major Players of Positive allosteric modulators Table 13. Major Players of Others Table 14. Global GABA Receptor Agonists Sales by Pharmacological Action Mode (2021-2026) & (K Dose) Table 15. Global GABA Receptor Agonists Sales Market Share by Pharmacological Action Mode (2021-2026) Table 16. Global GABA Receptor Agonists Revenue by Pharmacological Action Mode (2021-2026) & ($ million) Table 17. Global GABA Receptor Agonists Revenue Market Share by Pharmacological Action Mode (2021-2026) Table 18. Global GABA Receptor Agonists Sale Price by Pharmacological Action Mode (2021-2026) & (USD/Pcs) Table 19. Major Players of Oral dosage forms Table 20. Major Players of Injectable dosage forms Table 21. Major Players of Others Table 22. Global GABA Receptor Agonists Sales by Dosage Form (2021-2026) & (K Dose) Table 23. Global GABA Receptor Agonists Sales Market Share by Dosage Form (2021-2026) Table 24. Global GABA Receptor Agonists Revenue by Dosage Form (2021-2026) & ($ million) Table 25. Global GABA Receptor Agonists Revenue Market Share by Dosage Form (2021-2026) Table 26. Global GABA Receptor Agonists Sale Price by Dosage Form (2021-2026) & (USD/Pcs) Table 27. Global GABA Receptor Agonists Sale by Application (2021-2026) & (K Dose) Table 28. Global GABA Receptor Agonists Sale Market Share by Application (2021-2026) Table 29. Global GABA Receptor Agonists Revenue by Application (2021-2026) & ($ million) Table 30. Global GABA Receptor Agonists Revenue Market Share by Application (2021-2026) Table 31. Global GABA Receptor Agonists Sale Price by Application (2021-2026) & (USD/Pcs) Table 32. Global GABA Receptor Agonists Sales by Company (2021-2026) & (K Dose) Table 33. Global GABA Receptor Agonists Sales Market Share by Company (2021-2026) Table 34. Global GABA Receptor Agonists Revenue by Company (2021-2026) & ($ millions) Table 35. Global GABA Receptor Agonists Revenue Market Share by Company (2021-2026) Table 36. Global GABA Receptor Agonists Sale Price by Company (2021-2026) & (USD/Pcs) Table 37. Key Manufacturers GABA Receptor Agonists Producing Area Distribution and Sales Area Table 38. Players GABA Receptor Agonists Products Offered Table 39. GABA Receptor Agonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) Table 40. New Products and Potential Entrants Table 41. Market M&A Activity & Strategy Table 42. Global GABA Receptor Agonists Sales by Geographic Region (2021-2026) & (K Dose) Table 43. Global GABA Receptor Agonists Sales Market Share Geographic Region (2021-2026) Table 44. Global GABA Receptor Agonists Revenue by Geographic Region (2021-2026) & ($ millions) Table 45. Global GABA Receptor Agonists Revenue Market Share by Geographic Region (2021-2026) Table 46. Global GABA Receptor Agonists Sales by Country/Region (2021-2026) & (K Dose) Table 47. Global GABA Receptor Agonists Sales Market Share by Country/Region (2021-2026) Table 48. Global GABA Receptor Agonists Revenue by Country/Region (2021-2026) & ($ millions) Table 49. Global GABA Receptor Agonists Revenue Market Share by Country/Region (2021-2026) Table 50. Americas GABA Receptor Agonists Sales by Country (2021-2026) & (K Dose) Table 51. Americas GABA Receptor Agonists Sales Market Share by Country (2021-2026) Table 52. Americas GABA Receptor Agonists Revenue by Country (2021-2026) & ($ millions) Table 53. Americas GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose) Table 54. Americas GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose) Table 55. APAC GABA Receptor Agonists Sales by Region (2021-2026) & (K Dose) Table 56. APAC GABA Receptor Agonists Sales Market Share by Region (2021-2026) Table 57. APAC GABA Receptor Agonists Revenue by Region (2021-2026) & ($ millions) Table 58. APAC GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose) Table 59. APAC GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose) Table 60. Europe GABA Receptor Agonists Sales by Country (2021-2026) & (K Dose) Table 61. Europe GABA Receptor Agonists Revenue by Country (2021-2026) & ($ millions) Table 62. Europe GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose) Table 63. Europe GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose) Table 64. Middle East & Africa GABA Receptor Agonists Sales by Country (2021-2026) & (K Dose) Table 65. Middle East & Africa GABA Receptor Agonists Revenue Market Share by Country (2021-2026) Table 66. Middle East & Africa GABA Receptor Agonists Sales by Type (2021-2026) & (K Dose) Table 67. Middle East & Africa GABA Receptor Agonists Sales by Application (2021-2026) & (K Dose) Table 68. Key Market Drivers & Growth Opportunities of GABA Receptor Agonists Table 69. Key Market Challenges & Risks of GABA Receptor Agonists Table 70. Key Industry Trends of GABA Receptor Agonists Table 71. GABA Receptor Agonists Raw Material Table 72. Key Suppliers of Raw Materials Table 73. GABA Receptor Agonists Distributors List Table 74. GABA Receptor Agonists Customer List Table 75. Global GABA Receptor Agonists Sales Forecast by Region (2027-2032) & (K Dose) Table 76. Global GABA Receptor Agonists Revenue Forecast by Region (2027-2032) & ($ millions) Table 77. Americas GABA Receptor Agonists Sales Forecast by Country (2027-2032) & (K Dose) Table 78. Americas GABA Receptor Agonists Annual Revenue Forecast by Country (2027-2032) & ($ millions) Table 79. APAC GABA Receptor Agonists Sales Forecast by Region (2027-2032) & (K Dose) Table 80. APAC GABA Receptor Agonists Annual Revenue Forecast by Region (2027-2032) & ($ millions) Table 81. Europe GABA Receptor Agonists Sales Forecast by Country (2027-2032) & (K Dose) Table 82. Europe GABA Receptor Agonists Revenue Forecast by Country (2027-2032) & ($ millions) Table 83. Middle East & Africa GABA Receptor Agonists Sales Forecast by Country (2027-2032) & (K Dose) Table 84. Middle East & Africa GABA Receptor Agonists Revenue Forecast by Country (2027-2032) & ($ millions) Table 85. Global GABA Receptor Agonists Sales Forecast by Type (2027-2032) & (K Dose) Table 86. Global GABA Receptor Agonists Revenue Forecast by Type (2027-2032) & ($ millions) Table 87. Global GABA Receptor Agonists Sales Forecast by Application (2027-2032) & (K Dose) Table 88. Global GABA Receptor Agonists Revenue Forecast by Application (2027-2032) & ($ millions) Table 89. Sanofi Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 90. Sanofi GABA Receptor Agonists Product Portfolios and Specifications Table 91. Sanofi GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 92. Sanofi Main Business Table 93. Sanofi Latest Developments Table 94. Roche Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 95. Roche GABA Receptor Agonists Product Portfolios and Specifications Table 96. Roche GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 97. Roche Main Business Table 98. Roche Latest Developments Table 99. Novartis Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 100. Novartis GABA Receptor Agonists Product Portfolios and Specifications Table 101. Novartis GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 102. Novartis Main Business Table 103. Novartis Latest Developments Table 104. Viatris Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 105. Viatris GABA Receptor Agonists Product Portfolios and Specifications Table 106. Viatris GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 107. Viatris Main Business Table 108. Viatris Latest Developments Table 109. Teva Pharmaceutical Industries Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 110. Teva Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications Table 111. Teva Pharmaceutical Industries GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 112. Teva Pharmaceutical Industries Main Business Table 113. Teva Pharmaceutical Industries Latest Developments Table 114. Sandoz Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 115. Sandoz GABA Receptor Agonists Product Portfolios and Specifications Table 116. Sandoz GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 117. Sandoz Main Business Table 118. Sandoz Latest Developments Table 119. Lundbeck Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 120. Lundbeck GABA Receptor Agonists Product Portfolios and Specifications Table 121. Lundbeck GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 122. Lundbeck Main Business Table 123. Lundbeck Latest Developments Table 124. Biocodex Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 125. Biocodex GABA Receptor Agonists Product Portfolios and Specifications Table 126. Biocodex GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 127. Biocodex Main Business Table 128. Biocodex Latest Developments Table 129. Immedica Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 130. Immedica Pharma GABA Receptor Agonists Product Portfolios and Specifications Table 131. Immedica Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 132. Immedica Pharma Main Business Table 133. Immedica Pharma Latest Developments Table 134. Azurity Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 135. Azurity Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications Table 136. Azurity Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 137. Azurity Pharmaceuticals Main Business Table 138. Azurity Pharmaceuticals Latest Developments Table 139. Amneal Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 140. Amneal Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications Table 141. Amneal Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 142. Amneal Pharmaceuticals Main Business Table 143. Amneal Pharmaceuticals Latest Developments Table 144. Fresenius Kabi Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 145. Fresenius Kabi GABA Receptor Agonists Product Portfolios and Specifications Table 146. Fresenius Kabi GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 147. Fresenius Kabi Main Business Table 148. Fresenius Kabi Latest Developments Table 149. Hikma Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 150. Hikma Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications Table 151. Hikma Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 152. Hikma Pharmaceuticals Main Business Table 153. Hikma Pharmaceuticals Latest Developments Table 154. Eagle Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 155. Eagle Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications Table 156. Eagle Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 157. Eagle Pharmaceuticals Main Business Table 158. Eagle Pharmaceuticals Latest Developments Table 159. PAION Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 160. PAION Pharma GABA Receptor Agonists Product Portfolios and Specifications Table 161. PAION Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 162. PAION Pharma Main Business Table 163. PAION Pharma Latest Developments Table 164. Mundipharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 165. Mundipharma GABA Receptor Agonists Product Portfolios and Specifications Table 166. Mundipharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 167. Mundipharma Main Business Table 168. Mundipharma Latest Developments Table 169. Eisai Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 170. Eisai GABA Receptor Agonists Product Portfolios and Specifications Table 171. Eisai GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 172. Eisai Main Business Table 173. Eisai Latest Developments Table 174. Sumitomo Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 175. Sumitomo Pharma GABA Receptor Agonists Product Portfolios and Specifications Table 176. Sumitomo Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 177. Sumitomo Pharma Main Business Table 178. Sumitomo Pharma Latest Developments Table 179. ANI Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 180. ANI Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications Table 181. ANI Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 182. ANI Pharmaceuticals Main Business Table 183. ANI Pharmaceuticals Latest Developments Table 184. Zydus Lifesciences Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 185. Zydus Lifesciences GABA Receptor Agonists Product Portfolios and Specifications Table 186. Zydus Lifesciences GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 187. Zydus Lifesciences Main Business Table 188. Zydus Lifesciences Latest Developments Table 189. Aurobindo Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 190. Aurobindo Pharma GABA Receptor Agonists Product Portfolios and Specifications Table 191. Aurobindo Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 192. Aurobindo Pharma Main Business Table 193. Aurobindo Pharma Latest Developments Table 194. Sun Pharmaceutical Industries Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 195. Sun Pharmaceutical Industries GABA Receptor Agonists Product Portfolios and Specifications Table 196. Sun Pharmaceutical Industries GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 197. Sun Pharmaceutical Industries Main Business Table 198. Sun Pharmaceutical Industries Latest Developments Table 199. Cipla Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 200. Cipla GABA Receptor Agonists Product Portfolios and Specifications Table 201. Cipla GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 202. Cipla Main Business Table 203. Cipla Latest Developments Table 204. Torrent Pharmaceuticals Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 205. Torrent Pharmaceuticals GABA Receptor Agonists Product Portfolios and Specifications Table 206. Torrent Pharmaceuticals GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 207. Torrent Pharmaceuticals Main Business Table 208. Torrent Pharmaceuticals Latest Developments Table 209. Endo Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 210. Endo GABA Receptor Agonists Product Portfolios and Specifications Table 211. Endo GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 212. Endo Main Business Table 213. Endo Latest Developments Table 214. Baxter Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 215. Baxter GABA Receptor Agonists Product Portfolios and Specifications Table 216. Baxter GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 217. Baxter Main Business Table 218. Baxter Latest Developments Table 219. Hameln Pharma Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 220. Hameln Pharma GABA Receptor Agonists Product Portfolios and Specifications Table 221. Hameln Pharma GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 222. Hameln Pharma Main Business Table 223. Hameln Pharma Latest Developments Table 224. Ethypharm Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 225. Ethypharm GABA Receptor Agonists Product Portfolios and Specifications Table 226. Ethypharm GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 227. Ethypharm Main Business Table 228. Ethypharm Latest Developments Table 229. Neuraxpharm Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 230. Neuraxpharm GABA Receptor Agonists Product Portfolios and Specifications Table 231. Neuraxpharm GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 232. Neuraxpharm Main Business Table 233. Neuraxpharm Latest Developments Table 234. Sawai Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 235. Sawai Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 236. Sawai Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 237. Sawai Pharmaceutical Main Business Table 238. Sawai Pharmaceutical Latest Developments Table 239. Towa Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 240. Towa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 241. Towa Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 242. Towa Pharmaceutical Main Business Table 243. Towa Pharmaceutical Latest Developments Table 244. Nichi-Iko Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 245. Nichi-Iko Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 246. Nichi-Iko Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 247. Nichi-Iko Pharmaceutical Main Business Table 248. Nichi-Iko Pharmaceutical Latest Developments Table 249. Zhejiang Jingxin Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 250. Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 251. Zhejiang Jingxin Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 252. Zhejiang Jingxin Pharmaceutical Main Business Table 253. Zhejiang Jingxin Pharmaceutical Latest Developments Table 254. Jiangsu Nhwa Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 255. Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 256. Jiangsu Nhwa Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 257. Jiangsu Nhwa Pharmaceutical Main Business Table 258. Jiangsu Nhwa Pharmaceutical Latest Developments Table 259. Yichang Humanwell Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 260. Yichang Humanwell Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 261. Yichang Humanwell Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 262. Yichang Humanwell Pharmaceutical Main Business Table 263. Yichang Humanwell Pharmaceutical Latest Developments Table 264. Shandong Sine Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 265. Shandong Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 266. Shandong Sine Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 267. Shandong Sine Pharmaceutical Main Business Table 268. Shandong Sine Pharmaceutical Latest Developments Table 269. Shanghai SPH Sine Pharmaceutical Basic Information, GABA Receptor Agonists Manufacturing Base, Sales Area and Its Competitors Table 270. Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Product Portfolios and Specifications Table 271. Shanghai SPH Sine Pharmaceutical GABA Receptor Agonists Sales (K Dose), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 272. Shanghai SPH Sine Pharmaceutical Main Business Table 273. Shanghai SPH Sine Pharmaceutical Latest Developments List of Figures Figure 1. Picture of GABA Receptor Agonists Figure 2. GABA Receptor Agonists Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global GABA Receptor Agonists Sales Growth Rate 2021-2032 (K Dose) Figure 7. Global GABA Receptor Agonists Revenue Growth Rate 2021-2032 ($ millions) Figure 8. GABA Receptor Agonists Sales by Geographic Region (2021, 2025 & 2032) & ($ millions) Figure 9. GABA Receptor Agonists Sales Market Share by Country/Region (2025) Figure 10. GABA Receptor Agonists Sales Market Share by Country/Region (2021, 2025 & 2032) Figure 11. Product Picture of GABA_A receptor-targeted drugs Figure 12. Product Picture of GABA_B receptor-targeted drugs Figure 13. Product Picture of Others Figure 14. Global GABA Receptor Agonists Sales Market Share by Type in 2026 Figure 15. Global GABA Receptor Agonists Revenue Market Share by Type (2021-2026) Figure 16. Product Picture of Direct GABA receptor agonists Figure 17. Product Picture of Positive allosteric modulators Figure 18. Product Picture of Others Figure 19. Global GABA Receptor Agonists Sales Market Share by Pharmacological Action Mode in 2026 Figure 20. Global GABA Receptor Agonists Revenue Market Share by Pharmacological Action Mode (2021-2026) Figure 21. Product Picture of Oral dosage forms Figure 22. Product Picture of Injectable dosage forms Figure 23. Product Picture of Others Figure 24. Global GABA Receptor Agonists Sales Market Share by Dosage Form in 2026 Figure 25. Global GABA Receptor Agonists Revenue Market Share by Dosage Form (2021-2026) Figure 26. GABA Receptor Agonists Consumed in Attention Deficit Hyperactivity Disorder (ADHD) Figure 27. Global GABA Receptor Agonists Market: Attention Deficit Hyperactivity Disorder (ADHD) (2021-2026) & (K Dose) Figure 28. GABA Receptor Agonists Consumed in Psychiatric Disorders and Depression Figure 29. Global GABA Receptor Agonists Market: Psychiatric Disorders and Depression (2021-2026) & (K Dose) Figure 30. GABA Receptor Agonists Consumed in Alzheimer Figure 31. Global GABA Receptor Agonists Market: Alzheimer (2021-2026) & (K Dose) Figure 32. GABA Receptor Agonists Consumed in Epilepsy and Seizure Figure 33. Global GABA Receptor Agonists Market: Epilepsy and Seizure (2021-2026) & (K Dose) Figure 34. GABA Receptor Agonists Consumed in Anxiety and Sleep Disorders Figure 35. Global GABA Receptor Agonists Market: Anxiety and Sleep Disorders (2021-2026) & (K Dose) Figure 36. GABA Receptor Agonists Consumed in Obesity and Alcoholism Figure 37. Global GABA Receptor Agonists Market: Obesity and Alcoholism (2021-2026) & (K Dose) Figure 38. Global GABA Receptor Agonists Sale Market Share by Application (2025) Figure 39. Global GABA Receptor Agonists Revenue Market Share by Application in 2025 Figure 40. GABA Receptor Agonists Sales by Company in 2025 (K Dose) Figure 41. Global GABA Receptor Agonists Sales Market Share by Company in 2025 Figure 42. GABA Receptor Agonists Revenue by Company in 2025 ($ millions) Figure 43. Global GABA Receptor Agonists Revenue Market Share by Company in 2025 Figure 44. Global GABA Receptor Agonists Sales Market Share by Geographic Region (2021-2026) Figure 45. Global GABA Receptor Agonists Revenue Market Share by Geographic Region in 2025 Figure 46. Americas GABA Receptor Agonists Sales 2021-2026 (K Dose) Figure 47. Americas GABA Receptor Agonists Revenue 2021-2026 ($ millions) Figure 48. APAC GABA Receptor Agonists Sales 2021-2026 (K Dose) Figure 49. APAC GABA Receptor Agonists Revenue 2021-2026 ($ millions) Figure 50. Europe GABA Receptor Agonists Sales 2021-2026 (K Dose) Figure 51. Europe GABA Receptor Agonists Revenue 2021-2026 ($ millions) Figure 52. Middle East & Africa GABA Receptor Agonists Sales 2021-2026 (K Dose) Figure 53. Middle East & Africa GABA Receptor Agonists Revenue 2021-2026 ($ millions) Figure 54. Americas GABA Receptor Agonists Sales Market Share by Country in 2025 Figure 55. Americas GABA Receptor Agonists Revenue Market Share by Country (2021-2026) Figure 56. Americas GABA Receptor Agonists Sales Market Share by Type (2021-2026) Figure 57. Americas GABA Receptor Agonists Sales Market Share by Application (2021-2026) Figure 58. United States GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 59. Canada GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 60. Mexico GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 61. Brazil GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 62. APAC GABA Receptor Agonists Sales Market Share by Region in 2025 Figure 63. APAC GABA Receptor Agonists Revenue Market Share by Region (2021-2026) Figure 64. APAC GABA Receptor Agonists Sales Market Share by Type (2021-2026) Figure 65. APAC GABA Receptor Agonists Sales Market Share by Application (2021-2026) Figure 66. China GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 67. Japan GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 68. South Korea GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 69. Southeast Asia GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 70. India GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 71. Australia GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 72. China Taiwan GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 73. Europe GABA Receptor Agonists Sales Market Share by Country in 2025 Figure 74. Europe GABA Receptor Agonists Revenue Market Share by Country (2021-2026) Figure 75. Europe GABA Receptor Agonists Sales Market Share by Type (2021-2026) Figure 76. Europe GABA Receptor Agonists Sales Market Share by Application (2021-2026) Figure 77. Germany GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 78. France GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 79. UK GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 80. Italy GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 81. Russia GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 82. Middle East & Africa GABA Receptor Agonists Sales Market Share by Country (2021-2026) Figure 83. Middle East & Africa GABA Receptor Agonists Sales Market Share by Type (2021-2026) Figure 84. Middle East & Africa GABA Receptor Agonists Sales Market Share by Application (2021-2026) Figure 85. Egypt GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 86. South Africa GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 87. Israel GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 88. Turkey GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 89. GCC Countries GABA Receptor Agonists Revenue Growth 2021-2026 ($ millions) Figure 90. Manufacturing Cost Structure Analysis of GABA Receptor Agonists in 2026 Figure 91. Manufacturing Process Analysis of GABA Receptor Agonists Figure 92. Industry Chain Structure of GABA Receptor Agonists Figure 93. Channels of Distribution Figure 94. Global GABA Receptor Agonists Sales Market Forecast by Region (2027-2032) Figure 95. Global GABA Receptor Agonists Revenue Market Share Forecast by Region (2027-2032) Figure 96. Global GABA Receptor Agonists Sales Market Share Forecast by Type (2027-2032) Figure 97. Global GABA Receptor Agonists Revenue Market Share Forecast by Type (2027-2032) Figure 98. Global GABA Receptor Agonists Sales Market Share Forecast by Application (2027-2032) Figure 99. Global GABA Receptor Agonists Revenue Market Share Forecast by Application (2027-2032)
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の 医薬品・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（receptor）の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
